GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » EV-to-EBITDA

Qiagen NV (Qiagen NV) EV-to-EBITDA : 14.95 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Qiagen NV EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Qiagen NV's enterprise value is $9,568 Mil. Qiagen NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $640 Mil. Therefore, Qiagen NV's EV-to-EBITDA for today is 14.95.

The historical rank and industry rank for Qiagen NV's EV-to-EBITDA or its related term are showing as below:

QGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.38   Med: 19.25   Max: 47.92
Current: 14.95

During the past 13 years, the highest EV-to-EBITDA of Qiagen NV was 47.92. The lowest was 11.38. And the median was 19.25.

QGEN's EV-to-EBITDA is ranked better than
53.85% of 117 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.18 vs QGEN: 14.95

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Qiagen NV's stock price is $41.08. Qiagen NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $1.526. Therefore, Qiagen NV's PE Ratio for today is 26.92.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Qiagen NV EV-to-EBITDA Historical Data

The historical data trend for Qiagen NV's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV EV-to-EBITDA Chart

Qiagen NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.05 18.55 15.10 15.17 15.08

Qiagen NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.17 15.98 17.15 15.35 15.08

Competitive Comparison of Qiagen NV's EV-to-EBITDA

For the Diagnostics & Research subindustry, Qiagen NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen NV's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Qiagen NV's EV-to-EBITDA falls into.



Qiagen NV EV-to-EBITDA Calculation

Qiagen NV's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=9567.610/640.121
=14.95

Qiagen NV's current Enterprise Value is $9,568 Mil.
Qiagen NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $640 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qiagen NV  (NYSE:QGEN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Qiagen NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=41.08/1.526
=26.92

Qiagen NV's share price for today is $41.08.
Qiagen NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.526.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Qiagen NV EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Qiagen NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Qiagen NV (Qiagen NV) Business Description

Address
Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Executives
Prof. Dr. Elaine R. Mardis Supervisory Board
Roland Sackers Board of Directors
Thierry Bernard Board of Directors
Lawrence A. Rosen Supervisory Board